China (Mainland)
Entecavir hydrate 209216-23-9 CAS NO.209216-23-9
- FOB Price: USD: 1.00-1.00 /Gram Get Latest Price
- Min.Order: 10 Gram
- Payment Terms: L/C,T/T,
- Available Specifications:
99.9%(1-10)Gram
- Product Details
Keywords
- Entecavir cas209216-23-9
- Entecavir Entecavir
- Entecavir
Quick Details
- ProName: Entecavir hydrate 209216-23-9
- CasNo: 209216-23-9
- Molecular Formula: C12H15N5O3
- Appearance: powder
- Application: Entecavir monohydrate Pharmaceutical ...
- DeliveryTime: According to the contract requirements
- PackAge: fiber can/aluminum foil bag
- Port: china（qingdao/beijing/shanghai/hangzho...
- ProductionCapacity: 10 Kilogram/Day
- Purity: 99.0%
- Storage: 20-25℃
- Transportation: by air/by sea
- LimitNum: 10 Gram
- Grade: Pharma Grade,Electron Grade
- 99.9%: 99.9%
- assay: 99.9%
- High Purity: 99.9%
- Grade: Pharma Grade
- Standard: EP9, USP40
Superiority
Entecavir , Entecavir,
Entecavir abbreviated ETV, is an oral antiviral drugused in the treatment of hepatitis B infection. It is marketed under the trade names Baraclude (BMS) and Entaliv (DRL).
Entecavir , Entecavir,
Entecavir abbreviated ETV, is an oral antiviral drugused in the treatment of hepatitis B infection. It is marketed under the trade names Baraclude (BMS) and Entaliv (DRL).
Entecavir , Entecavir,
Entecavir abbreviated ETV, is an oral antiviral drugused in the treatment of hepatitis B infection. It is marketed under the trade names Baraclude (BMS) and Entaliv (DRL).
Entecavir is a nucleoside analog[1] (more specifically, a guanosineanalogue) that inhibits reverse transcription, DNA replication andtranscription in the viral replication process. The drug's manufacturer claims that entecavir is more efficacious than previous agents used to treat hepatitis B (lamivudine and adefovir).
Details
 |
|
|---|---|
| Systematic (IUPAC) name | |
| 2-Amino-9-[(1S,3R,4S)-4-hydroxy-3-(hydroxymethyl)-2-methylidenecyclopentyl]-6,9-dihydro-3H-purin-6-one | |
| Clinical data | |
| Trade names | Baraclude |
| AHFS/Drugs.com | monograph |
| MedlinePlus | a605028 |
| Licence data | EMA:Link, US FDA:link |
| Pregnancy cat. | C (US) |
| Legal status | -only (US) |
| Routes | Oral |
| Pharmacokinetic data | |
| Protein binding | 13% |
| Half-life | 128–149 hours |
| Excretion | Renal 62–73% |
| Identifiers | |
| CAS number |
142217-69-4  |
| ATC code | J05AF10 |
| PubChem | CID 153941 |
| DrugBank | DB00442 |
| ChemSpider |
135679  |
| UNII |
NNU2O4609D |
| KEGG |
D04008 |
| ChEBI |
CHEBI:59902 |
| ChEMBL |
CHEMBL713 |
| Chemical data | |
| Formula | C12H15N5O3 |
| Mol. mass | 277.279 g/mol |